Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*

Results from the first-ever randomized control trial for the REGENETEN Implant in partial-thickness rotator cuff repair SmithNephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces compelling new randomized control trial (RCT) data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the REGENETEN Bioinductive Implant in isolation.